|Solid Phase Sandwich ELISA|
|For the quantitative determination of Human Neuropilin-2 / NRP2 concentration in serum.|
The use of this kit for other sample types need be validated by the end user due to the complexity of natural targets and unpredictable interference.
|The minimum detectable dose of Human Neuropilin-2 / NRP2 is typically less than 7.95 pg/mL. The MDD was determined by adding three standard deviations to the mean optical density value of twenty zero standard replicates and calculating the corresponding concentration.|
|1. 96 well microplate coated with Capture Antibody|
2. Detection Antibody conjugated to HRP
4. Wash Buffer Concentrate
5. Dilution Buffer Concentrate
6. Color Reagent A
7. Color Reagent B
8. Stop Solution
|Unopened Kit: Store at 2 - 8℃|
Opened/Reconstituted Reagents: Please refer to CoA
Neuropilin-2 (NRP-2) which is related to NRP-1, is a type I? transmembrane glycoprotein and has the structure characteristic with five main extracellular domains: two complement binding (CUB) domains, two coagulation factor V/VIII homology domains, and a MAM (meprin, tyrosine phosphatase domain) region. NRP-2 is a receptor capable of binding two disparate ligands, classⅢ semaphorins (SEMA) and vascular endothelial growth factors (VEGF), and thus regulates two diverse systems by activating cellular signaling pathways via interacting with other cell surface receptors such as VEGF receptors and plexins. NRP-2 is well known for its role in facilitating axonal guidance during the development of the neuronal system, and additionally, it is also expressed in vascular endothelial cells and lymphatic endothelium where it affects proliferation, migration, angiogenesis, as well as formation of small lymphatic vessels and capillaries. Recent study has identified NRP-2 as a polysialylated protein expressed in human dendritic cells and modulates DC-T cell Interactions. Nearly all tumor cells express neuropilins and NRP-2 is predominantly expressed in neuronal tumors and melanomas. Furthermore, it is suggested that as the specific ligand for NRP-2, SEMA 3F inhibits tumor angiogenesis and metastasis.